U.S. markets close in 5 hours 24 minutes
  • S&P 500

    3,756.86
    -28.52 (-0.75%)
     
  • Dow 30

    30,515.43
    -260.00 (-0.84%)
     
  • Nasdaq

    10,942.31
    -86.43 (-0.78%)
     
  • Russell 2000

    1,705.58
    -2.41 (-0.14%)
     
  • Crude Oil

    107.49
    +1.73 (+1.64%)
     
  • Gold

    1,801.00
    -6.30 (-0.35%)
     
  • Silver

    19.62
    -0.73 (-3.57%)
     
  • EUR/USD

    1.0381
    -0.0102 (-0.98%)
     
  • 10-Yr Bond

    2.8150
    -0.1570 (-5.28%)
     
  • GBP/USD

    1.2000
    -0.0175 (-1.44%)
     
  • USD/JPY

    134.8740
    -0.8540 (-0.63%)
     
  • BTC-USD

    19,317.44
    +296.79 (+1.56%)
     
  • CMC Crypto 200

    414.81
    -5.33 (-1.27%)
     
  • FTSE 100

    7,155.00
    -14.28 (-0.20%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Advicenne Reports 2021 Sales up 20% to €3.3 Million

·2 min read

PARIS, January 18, 2022--(BUSINESS WIRE)--Regulatory News:

Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces today sales of €3.3 million in 2021, representing a 20% growth from the previous year (2020: €2.7 million).

The growth has been driven by sales of Sibnayal™ which reached €1.0 million in 2021 (2020: €0.8 million). Sibnayal™ is the first and only label-approved drug for the treatment of distal Renal Tubular Acidosis (dRTA) in adults, adolescents, and children aged one year and older.

The sales of Sibnayal™ were generated within the framework of the numerous European Early Access Programs (EAP) covering the early availability of the drug in nearly 100 European patients with dRTA. In addition to this, Advicenne has recently signed distribution agreements for the commercialization of Sibnayal™ covering the Nordic countries, Benelux and Central and Eastern Europe with partners from the European alliance "Your Pharma Partners". In the UK, an annual cost of treatment equivalent to around €11,000 has recently been set by the National Health Service (NHS). Finally, In France, Sibnayal™ is eligible for reimbursement and benefits from a Level IV ASMR.

Sales in the Company’s neurology franchise have grown 19% to €2.3 million (2020: €1.9 million), mostly driven by the sustained strong performance of Likozam, a medicine for the treatment of severe epilepsy in children.

(€ million)

2021

2020

Growth

Sibnayal™

1.0

0.8

+24%

Neurology

2.3

1.9

+19%

Total

3.3

2.7

+20%

About Advicenne
Advicenne (Euronext: ADVIC) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product SibnayalTM (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US. Headquartered in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019.

For additional information see: https://advicenne.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220117005460/en/

Contacts

Advicenne
Didier Laurens, CEO
+33 (0) 1 87 44 40 17
Email: investors@advicenne.com

Ulysse Communication
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: advicenne@ulysse-communication.com

Consilium Strategic Communications
Mary-Jane Elliott, Ashley Tapp, Davide Salvi
+44 (0)20 3709 5700
Email: advicenne@consilium-comms.com